Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of “Reduce” from Analysts

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned an average rating of “Reduce” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a sell recommendation, three have given a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $2.4714.

A number of equities analysts recently issued reports on DH shares. Bank of America reiterated an “underperform” rating and issued a $0.70 target price on shares of Definitive Healthcare in a report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Zacks Research upgraded shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Barclays dropped their price objective on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a research note on Monday, March 30th. Finally, Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a report on Friday, May 8th.

Definitive Healthcare Stock Down 3.7%

Shares of NASDAQ:DH opened at $0.80 on Thursday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.75 and a current ratio of 1.75. Definitive Healthcare has a 52-week low of $0.62 and a 52-week high of $4.70. The business’s 50 day simple moving average is $0.87 and its two-hundred day simple moving average is $1.46. The firm has a market cap of $84.41 million, a P/E ratio of -0.49, a PEG ratio of 11.17 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $55.93 million during the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. As a group, research analysts forecast that Definitive Healthcare will post 0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DH. AQR Capital Management LLC boosted its position in shares of Definitive Healthcare by 56.7% during the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock valued at $1,706,000 after buying an additional 213,562 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after buying an additional 7,404,363 shares during the last quarter. Jane Street Group LLC raised its position in Definitive Healthcare by 166.0% in the 1st quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock valued at $304,000 after buying an additional 65,597 shares during the last quarter. Creative Planning lifted its stake in Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after acquiring an additional 8,428 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in Definitive Healthcare during the 2nd quarter valued at $4,247,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.